Precision Medicine in Gynecologic Cancers: Expert Answers to Your Questions
In this podcast episode, listen to Linda R. Duska, MD, MPH; Robert L. Coleman, MD, FACOG, FACS; and Leslie Randall, MD, MAS, as they answer questions on managing patients with endometrial or ovarian cancers based on the latest evidence.
Decera Clinical Education Oncology Podcast · Linda R Duska MD MPH, Robert L Coleman MD FACOG FACS, Leslie Randall MD MAS
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Linda R. Duska, MD, MPH; Robert L. Coleman, MD, FACOG, FACS; and Leslie Randall, MD, MAS, answer questions from an audience of healthcare professionals on topics related to the management of patients with endometrial and ovarian cancer including:
- Adding bevacizumab to chemotherapy in frontline endometrial cancer
- Lenvatinib and pembrolizumab in MSI-H/dMMR endometrial cancer
- PARP inhibitor maintenance in ovarian cancer
- Bevacizumab with or without PARP inhibitors in ovarian cancer
Presenters:
Linda R. Duska, MD, MPH
Lawrence W. Penniston MD Family Professor in Women’s Oncology Research
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia
Robert L. Coleman, MD, FACOG, FACS
Gynecologic Oncologist and Chief Scientific Officer
US Oncology, US Oncology Research
The Woodlands, Texas
Leslie Randall, MD, MAS
Diane Harris Wright Professor and Director
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Massey Cancer Center
Virginia Commonwealth University
Richmond, Virginia
Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/3e6pZCM
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.